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Abstract: Progressive forms of multiple sclerosis (MS) are associated with chronic demyelination,
axonal loss, neurodegeneration, cortical and deep gray matter damage, and atrophy. These changes
are strictly associated with compartmentalized sustained inflammation within the brain parenchyma,
the leptomeninges, and the cerebrospinal fluid. In progressive MS, molecular mechanisms underlying
active demyelination differ from processes that drive neurodegeneration at cortical and subcortical
locations. The widespread pattern of neurodegeneration is consistent with mechanisms associated
with the inflammatory molecular load of the cerebrospinal fluid. This is at variance with gray
matter demyelination that typically occurs at focal subpial sites, in the proximity of ectopic
meningeal lymphoid follicles. Accordingly, it is possible that variations in the extent and location
of neurodegeneration may be accounted for by individual differences in CSF flow, and by the
composition of soluble inflammatory factors and their clearance. In addition, “double hit” damage
may occur at sites allowing a bidirectional exchange between interstitial fluid and CSF, such as
the Virchow–Robin spaces and the periventricular ependymal barrier. An important aspect of CSF
inflammation and deep gray matter damage in MS involves dysfunction of the blood–cerebrospinal
fluid barrier and inflammation in the choroid plexus. Here, we provide a comprehensive review on the
role of intrathecal inflammation compartmentalized to CNS and non-neural tissues in progressive MS.
Keywords: inflammation; demyelination; neurodegeneration; cytokines; meninges; ependyma;
cerebrospinal fluid; choroid plexus; autoimmunity
1. Introduction
Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by white matter and gray
matter demyelination, axonal loss, and neurodegeneration [1]. MS displays heterogeneity in clinical
manifestations and outcome, in addition to distinctive clinical courses, including relapsing/remitting
MS (RRMS), secondary progressive MS (SPMS), or primary progressive (PPMS) [2]. Whilst acute cellular
inflammation with breakdown of the blood–brain barrier (BBB) is observed in RRMS, progressive
disease is associated with compartmentalized chronic inflammation at leptomeninges and brain
parenchyma, in the presence of an intact BBB [3]. In progressive MS, parenchymal inflammation is
sustained by perivascular infiltrates of tissue-resident memory T cells, lesion border macrophages,
and activated microglia. Owing to its gradual progression and clinical heterogeneity, the transition
from RRMS to SPMS is difficult to define based on clinical features and can result in diagnostic and
treatment delay.
Recent research on MS has provided insights into pathogenetic mechanisms governing the
progressive forms of the disease, which are characterized by increasing disability, neurodegeneration,
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and gray matter atrophy. These changes are thought to be the effect of mechanisms triggered by
compartmentalized chronic innate and adaptive immune responses in the brain parenchyma and
CSF-filled regions and associated cells lining these areas [4]. The latter include the meninges and the
cerebrospinal fluid (CSF), which is in part secreted by epithelial cells of the choroid plexuses (CP) of
the brain’s ventricles, and the remaining half contributed by the interstitial fluid of the brain and by
the secretory epithelium of ependymal cells lining the cerebral ventricles [5,6].
At different interfaces between the blood–CNS and blood–non-neural tissues, including meningeal
membranes and choroid plexuses, blood vessels display distinctive cellular properties and biochemical
mechanisms that provide the basis for anatomical and immunological barriers. These barriers,
encompassing the BBB, the blood–meningeal barrier (BMB), and the blood–CSF (B-CSF) barrier,
regulate the active transport of small molecules while restricting the inward passage of cells and large
molecules [7]. Additionally, non-vascular barriers are provided by the epithelial arachnoid and pial
layers at the interface between the subarachnoid CSF and dura and pia mater and by the ependymal
barrier of glial cells exposed to ventricular CSF and brain interstitial fluid. Among BBB, B–CSF, and BMB,
immune cell entry into CNS and CSF occurs only through the endothelium of the cerebrovasculature
and the choroid plexus epithelium [8]. The precise mechanisms involved in compartmentalization of
cellular inflammation to distinctive intrathecal niches, such as meninges and CP, and their correlation
with damage to neighboring nervous tissues remain to be fully clarified. Over the last decade,
insight into pathogenetic mechanisms of MS has been gained from neuropathological studies of
post-mortem tissues and molecular proteomic analysis of blood/CSF [9,10], and this review describes
current knowledge about the role of intrathecal inflammation compartmentalized in the CSF and
non-neural tissues.
2. Meningeal Inflammation
Intracranial and intraspinal structures that wrap the brain include the three layers of meninges
consisting of the dura mater; the arachnoid mater, which is filled with the cerebrospinal fluid and
contains leptomeningeal vessels; and the densely vascularized pia mater [11,12]. The dural and
subdural meninges are mostly populated with macrophages, and to a lesser extent with resident and
circulating T cells, in addition to B cells, dendritic cells, and natural killer cells. These populations,
including cells of the innate and adaptive divisions and innate lymphoid elements, which incorporate
features of both innate and adaptive divisions, are collectively referred to as “meningeal immunity”
and are involved in meningeal immune surveillance and in exerting effector functions [13]. Beside the
heterogeneity in immune cellular composition, which is more complex within dural layers, meningeal
membranes are characterized by the presence of the arachnoid barrier (AB) cells at the interface with
the dura and the blood–meningeal barrier (Figure 1A,B). While the AB is considered an insurmountable
hurdle for the inward passage to the CSF of molecules released from leaky dural capillaries, and,
in addition, no evidence exists for the involvement of the dura mater in MS, the MRI detection of dural
nodular enhancement, close to veins and sinuses [14], remains to be elucidated.
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Figure 1. Schematic overview of “meningeal and choroid plexus immunity” (A,B) and pathological 
alterations in multiple sclerosis (MS) (C,D). (A): The meninges consist of different membranes, 
including the dura mater (periosteal and meningeal layers), the arachnoid, and the pia. Strands of 
connective tissue, or arachnoid trabeculae, extend from the arachnoid layer and contains the vascular 
system. Under physiological conditions, the subarachnoid space is populated by scattered B- and T-
Figure 1. Schematic overview of “meningeal and choroid plexus immunity” (A,B) and pathological
alterations in multiple sclerosis (MS) (C,D). (A): The meninges consist of different membranes, including
the dura mater (periosteal and meningeal layers), the arachnoid, and the pia. Strands of connective
tissue, or arachnoid trabeculae, extend from the arachnoid layer and contains the vascular system.
Under physiological conditions, the subarachnoid space is populated by scattered B- and T-cells,
plasma cells, and macrophages and is filled with the cerebrospinal fluid (CSF) bathing the cortical grey
matter (GM). (C): In MS, either innate or adaptive immune cells, in particular B-cells, accumulate in
the subarachnoid space, outside the meningeal vessel, and may form ectopic tertiary lymphoid-like
structures (TLSs), which are in close contact with the pia mater. This compartmentalized meningeal
inflammation may contribute to the release in the CSF of inflammatory mediators that diffuse through
the pia and induce subpial cortical demyelination. (B): The choroid plexus (CP) stroma is irrigated
by fenestrated microvessels allowing free diffusion of blood-borne molecules. The CP epithelium
surrounds the stroma and forms the blood–CSF barrier. Under physiological conditions, dendritic
cells, macrophages, and sparse T-cells are found in the choroid plexus stroma. (D): During chronic
neuroinflammation, both innate and adaptive immune cells accumulate in the choroid plexus and
release inflammatory and proinflammatory factors in the surrounding CSF. These inflammatory changes
may possibly induce changes in the structure and function of the ependyma lining the ventricle and
the sub-ependymal glia, similar to those observed in the subpial GM.
Over the last 15 years, intrathecal accumulation of B cells forming ectopic tertiary lymphoid-like
structures (TLSs), morphologically resembling B-cell follicles of secondary lymphoid follicles in
severe cases, has been demonstrated within the inflamed meninges of a subgroup of MS patients
with more rapid and severe disease progression [15–18] as well as in brain biopsies obtained from
patients with early stage MS [19] (Figure 1C). Similar ectopic TLSs have been previously detected
also in inflamed tissues in autoimmune conditions, such as rheumatoid arthritis, myasthenia gravis,
Hashimoto’s thyroiditis, and Sjögren’s syndrome; other chronic inflammatory diseases, including
ulcerative colitis and Chron’s diseases; infectious diseases—namely, chronic hepatitis C, and chronic
Lyme disease—in addition to many tumor types, and were considered as sites of chronic local
inflammation in the setting of systemic inflammatory diseases [20]. The degree of TLS organization
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correlates with tissue infiltration, indicating that induction of robust tertiary lymphoid organs (TLOs)
largely depends on the magnitude of local immune activation. Moreover, it has been suggested
that extant TLSs may engender local adaptive immune responses toward locally displayed antigens,
resulting in turn in a more aggressive disease with a poor prognosis, autoantibody production, and
increased risk for the development of malignancies in many non-neural tissues [21]. Typically, TLSs
develop during the transition from acute to chronic inflammation and are accompanied by the ectopic
expression of lymphoid chemokines CCL19, CCL21, CXCL13, and CXCL12. In particular, CXCL13 is
supplied by the predominant population of stromal cells in the B-cell follicle, the follicular dendritic
cells (FDCs) [20]. The presence of meningeal TLS in cerebral sulci of a subgroup of post-mortem MS
cases (accounting for about 40% of examined cohorts) correlated with the extent of subpial cortical
demyelination, also named type III cortical lesions, and more severe and rapid disease progression,
characterized by an early age of disability onset and early age of death in a subgroup of acute
and progressive MS cases with meningeal TLSs [16,22,23]. Furthermore, the presence of TLSs in
the meninges of MS cases was found to be linked to a “surface-in” gradient of subpial cortical
neurodegeneration and glia activation, significantly higher in the outer cortical layers, close to the
CSF surface, when compared to the inner ones [9], suggesting that the meningeal TLSs in MS may
represent intrathecal sources of inflammatory stimuli able to orchestrate a chronic local inflammatory
environment. These changes have also been confirmed in brain biopsies of early onset MS cases and
acute MS post-mortem brains [19,23,24]. More recently, the presence of lymphoid-like structures in
the forebrain meninges of post-mortem progressive MS cases was associated with increased spinal
cord meningeal inflammation, white and grey demyelination, and axon loss in motor and sensory
tracts [25]. All these data, supporting a key role for meningeal inflammation in both brain and spinal
cord locations in MS patients, suggest that the meninges may represent intracerebral/spinal niches
favoring lymphocyte accumulation and activity. This is possibly due to the early ingress of immune
cells across a compromised BBB, contributing therefore to the MS-specific compartmentalized chronic
inflammation within the CNS space.
3. Subpial Lesions
In view of recent advances in imaging techniques, including brain MRI and PET, combined with
the use of myelin immunohistochemistry in brain biopsies and post-mortem tissues, GM involvement
in MS is again receiving considerable attention. The high prevalence of demyelination in GM areas in
MS was originally detected by a study combining MRI and conventional histology in 12 post-mortem
brains [26]. Based on the regional distribution of cortical lesions it was hypothesized that the observed
pattern appeared to be causally related to the vascular anatomy, which resulted in the definition of
seven distinct types of cortical lesions. Peterson et al. investigated cortical lesions in postmortem MS
brains using myelin immunohistochemistry and proposed a classification system that distinguished
three major cortical lesion types [27]. This scoring system is currently widely used for classification
of cortical lesions in MS tissue and includes: (1) type 1 lesions, which are leukocortical areas of
demyelination, extending across both white matter and gray matter but sparing the surface of the brain;
(2) type 2 lesions, or “intracortical”, which are contained within the cerebral cortex grey matter and
often occur around a blood vessel; and (3) type 3 lesions, or “subpial”, often affecting an extensive area
of cortical demyelination (Figure 2A–D).
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Figure 2. Demyelinating cortical lesion and meningeal inflammation in chronic progressive MS.
Immunohistochemistry for myelin oligodendrocyte protein (MOG) shows extensive subpial
demyelination involving the neocortical grey atter, contiguous to MOG-positive brain tissue
(A, black arrowheads). Th esion is in clos proximity to inflamed me inges co taining an elevated
number of CD20+ B cells, either accumulated (B, arrow) or diffused (C), around subarachnoid vessels.
Substantial increased density of MHC-class II+ activated microglia can be observed in the most
external cortical layers (white arrowheads) at the pia/CSF boundary (D) nearby inflamed meninges.
Original magnifications: 50× (A), 100× (D), 200× (B,C).
In one study, type-1 leukocortical lesions accounted for 15.5% of total lesions and affected 14.4%
of the total cortical demyelinated area; type-2 intracortical lesions accounted for 16.5% of GM lesions
and 1.2% of the demyelinated area; and type-3 subpial lesions were 60% of the total lesions and
accounted fo 67% of the total cortical demyelinated area. A further type, classified as type 4, was
characterized by involvement of the whole cortical thickness and accounted for 8% of total lesions
and 17% of demyelinated area [28]. Notably, when this classification system was applied to biopsy
samples from patients with early stages of MS, 38% revealed clear evidence of cortical demyelination,
with type-1 lesions accounting for half of the total number, followed by type-3 and type-2 plaques [19].
More importantly, cortical subpial demyelination has been identified as a peculiar and distinctive
pattern occurring in a significant subpopulation of MS patients, particularly those with a long and
progressive disease course [28]. The solidity of these data has been assessed and validated by several
neuropathology studies [29,30].
A common appearance of type-3 lesions described in all neuropathology studies was that of long
cortical ribbons of subpial demyelination, often affecting several adjacent gyri and stopping close to
the WM boundary. Other type-3 lesions were wedge-shaped, with the base at the surface of the brain.
Additionally, a combination of these patterns, with wedge-like lesion areas within bands of more
superficial subpial demyelination, was often present [28].
Cortical grey matter lesions are characterized by a relative lack of lymphocyte infiltration,
complement deposition or BBB disruption, as compared to WM lesions [31–33]. Moreover,
cortical lesions are thought to be characterized by a dominant effector cell population of ramified
microglia rather than macrophages [27]. The changes seen in GM appeared less severe compared to
the WM and were not associated with increased cortical inflammation, astrogliosis, and complement
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deposition [33]. However, because of the anatomical proximity of the CSF space to the cortical GM,
one must consider possible bi-directional immune cell trafficking between the subarachnoid space and
the cortical parenchyma [34], or at least a degree of molecular exchange. Interstitial fluid in the subpial
GM drains preferentially along perivascular (Virchow–Robin) channels to the CSF, while interstitial
fluid in WM also spreads through the extracellular spaces between nerve fibers. In the WM of the brain,
this fluid predominantly drains into the ventricles. These observations suggest that several molecules,
in particular myelinotoxic substances, originating in the interstitial fluid could potentially circulate
within Virchow–Robin spaces (resulting in perivenular demyelination) and the CSF (mediating subpial
and periventricular demyelination), as will be extensively discussed below.
The diffusion of inflammatory molecules through Virchow–Robin spaces and pia mater may
support the finding of a substantial “surface-in” gradient of subpial cortical neurodegeneration and
glia activation, significantly higher in the outer cortical layers, close to the CSF surface, when compared
to the inner ones close to the WM boundary [9], in particularly in MS patients with meningeal
lymphoid-like structures. This cortical gradient has been replicated in vivo by surface-based analysis
of ultra-high resolution MRI acquisition at 7 T [35] and was found to be more severe in progressive
MS [36–38].
4. CSF Inflammation
Most of the MS-specific immunopathological features described above, in particular the intrathecal
inflammation, are poorly revealed by conventional clinical and radiological tools. However, recent
experimental evidence has suggested that CSF biomarkers may represent appropriate surrogates of MS
intrathecal inflammation and may play a key role in diagnostic accuracy and monitoring of patients.
Investigation of CSF has indeed regained attention in the last version of the McDonald diagnostic
criteria, which include the presence of oligoclonal bands [39].
In addition to the presence of oligoclonal bands and increased intrathecal IgG synthesis that
are indicative of chronic immune activation and represent a key diagnostic tool in MS, numerous
molecules have been examined, including markers of tissue damage, such as the neurofilament light
chain (NfL), and other biomarkers reflecting either pathophysiological processes (demyelination,
inflammation, and repair), or for improving diagnosis and predicting disease progression and clinical
outcome. The most desirable properties for biomarkers to be used in a clinical contest is that
they provide: (1) a reliable and clear differentiation between MS and other demyelinating diseases;
(2) an unambiguous distinction among relapsing and progressive MS courses; and (3) a predictable
measure of treatment efficacy.
The study of CSF biomarkers of intrathecal inflammation is not only relevant for their
diagnostic/prognostic role but also for elucidating molecular mechanisms of MS immunopathogenesis.
Areas of application of CSF biomarkers in MS can be grouped as follows:
1. Diagnostic, including antibodies against aquaporin 4 and MOG, vascular cell adhesion
molecules, glial fibrillary acidic protein (GFAP), complement components, cytokines (IL-6),
and chemokines CXCL13);
2. Prognostic, including chitinase 3- like1 (CHI3L1), CXCL13, GFAP;
3. Monitoring of therapy response and side effects, including CXCL13, IL-6, IL-8CHI3L1, sCD21,
sCD27 [40].
More recently, the integration of neuropathology with molecular and MRI methodologies has
contributed to our understanding that specific proinflammatory cytokines (IFNγ, TNF, IL2, and IL22)
and molecules related to sustained B-cell activity and lymphoid-neogenesis (CXCL13, CXCL10, LTα,
IL6, IL10), characterize MS cases with higher levels of meningeal inflammation and GM demyelination
at post-mortem analysis. The above CSF profile was also encountered in naive MS patients that at the
time of diagnosis had increased cortical lesion volume and number [41], and, in addition, was strongly
predictive of higher disease activity after 4 years of clinical and radiological longitudinal follow-up [42].
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All these data corroborate the hypothesis that meningeal infiltrates may constitute the main
source of CSF intrathecal inflammation [43], a view that has been recently confirmed by a new model
of MS-like cortical pathology obtained by injecting lentiviral transfer vectors into the sagittal sulcus
of Dark Agouti rats, in order to induce continuous expression of TNF + IFNγ. This experimental
procedure resulted in meningeal inflammation and cortical GM pathology similar to that observed in
MS patients [44].
At the same time, other studies suggested that several biomarkers, including IL12B, CD5, MIP1a,
CXCL9, CCL11, and CCL20, highlight the independent yet complementary importance of T cells
in disease pathogenesis [45]. Finally, iron homeostasis markers, such as sCD163 and hemoglobin,
together with proteins of the coagulation cascade (fibrinogen) may also demonstrate the potential CSF
signature of innate (monocyte/macrophage) activity at early disease stages [10].
5. Choroid Plexus Inflammation
The choroid plexus (CP) of the brain ventricles is a specialized structure composed of a connective
stroma containing fenestrated capillaries encased by a layer of cuboidal epithelial cells that are linked
by adherens junctions and apical tight junctions, and provide the anatomical substrate responsible for
the blood–CSF barrier [46,47]. The CP epithelium is in direct continuity with ependymal cells, which in
turn provide an immunological barrier between the CSF and the CNS, and also regulates bidirectional
molecular trafficking, circulation, clearance, and metabolism of the CSF. In addition to CSF secretion,
a function under the control of adrenergic and cholinergic innervation, the CP exerts a number of
vital functions, encompassing maintenance of ion homeostasis, clearance of waste products, hormone
production, and active transport of micronutrients and water-soluble vitamins [47] Moreover, the CP
plays a pivotal role in regulating trafficking of immune cells from and to the CSF and brain parenchyma
and in orchestrating an active immunosurveillance system. Under physiological conditions, the CP
stroma is an immunologically active compartment densely populated by MHC class II-expressing
M2-like macrophages, epiplexus Kolmer cells, and IL-10-producing myeloid dendritic cells, which
extend projections into the ventricles for antigen uptake and presentation to stromal effector/memory
CD4+ T cells, and additional cellular elements, such as NK cells and CD8+ effector/memory T cells [48].
Owing to its strategical location at the interface between blood and CSF, the CP has recently attracted
particular interest as a fundamental player in CNS immunosurveillance and as a key culprit in acute
and chronic neuroinflammation [49]. In parallel, attention is being devoted to the role of ependymal
cells under physiological conditions and in neuroinflammatory disorders associated with ependymal
dysfunction [50]. However, the role of CP in MS has been largely overlooked and unexplored compared
to meningeal inflammation.
In EAE, an experimental model for MS, neuroinflammation and demyelination are preceded by
increased expression of ICAM-1, VCAM-1, and MAdCAM-1 by the CP epithelium. These changes are
accompanied by leukocyte recruitment and focal necrosis of individual epithelial cells [51]. Moreover,
recent studies show that the CP activates immune signaling in response to peripheral inflammation,
thereby providing a compartmentalized niche for the homing of activated and proliferating CD4+
T cells [52]. While caution is necessary when translating experimental data to humans, a recent study
shows an increased number of granulocytes and CD8+ T cells, but not B cells and plasma cells, in the
CP stroma of subjects with progressive MS [53]. This is at variance with earlier reports showing an
increased number of macrophages, dendritic cells, T cells, and CD138+ plasma cells in CP stroma in
association with increased expression of VCAM-1 in endothelium capillaries [54]. Moreover, indirect
evidence of CP inflammation has been provided by studies showing an increase in B cells, plasma cells,
and memory and effector T cells in the CSF of patients with MS, a finding highly suggestive of their
passage through the CP [55,56]. Recently, we also observed CP inflammation in association with
periventricular deep GM demyelination in post-mortem brain tissues from subjects with chronic
progressive MS (Magliozzi, unpublished) (Figure 3A–F).
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separates the meninges (left) from the choroid plexus (right), and in the choroid plexus (E,F). Original 
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6. Conclusions 
It is now clear that intrathecal inflammation is a characteristic of the clinical and pathological 
progression in MS. The compartmentalized immune response in the CSF-filled compartments of the 
brain, namely the ventricular and subarachnoid spaces, is closely associated with chronic 
demyelination and neurodegeneration, particularly in the cortical GM. Recent studies of cellular 
trafficking and molecular exchange between these compartments and the composition of the CSF has 
given rise to the hypothesis that a proinflammatory milieu can have damaging consequences to the 
tissues being bathed. Further studies are now required to identify the mechanisms by which 
intrathecal inflammation is promoted and maintained so that a rational approach can be developed 
for inhibiting the pathological progression. 
Figure 3. Periventricular demyelination and choroid plexus inflammation in chronic progressive
MS. Immunohistochemistry for myelin oligodendrocyte protein (MOG) discloses subependymal
demyelination (A) and an elevated number of MHC-class II+ activated microglia/macrophages (B) in the
choroid plexus (arrows) and at the boundary ependyma/CSF (arrowheads). Elev ted number of CD20+
B cells (C,E) and CD3+ T cells (D,F) are detected close to the tela chor idea (C,D), which separates the
meninges (left) from the choroid plexus (right), and in the choroid plexus (E,F). Original magnifications:
100× (A–F).
The role of the choroid plexus and of the ependymal barrier warrants more attention in future
studies of inflammatory neurological conditions, and specifically in demyelinating disorders to assess
cellular trafficking (Figure 1D).
6. Conclus o s
It is now cle r that intrathecal inflammation is a characteristic of the cli ical and pathological
progression i MS. T e compartmentalized immune response in the CSF-filled compartments of
the brain, namely the ventricular and subarachnoid spaces, is closely associated with chronic
demyelination and neurodegeneration, particularly in the cortical GM. Recent studies of cellular
trafficking and molecular exchange between these compartments and the composition of the CSF has
given rise to the hypothesis that a proinflammatory milieu can have damaging consequences to the
tissues being bathed. Further studies are now required to identify the mechanisms by which intrathecal
inflammation is promoted and maintained so that a rational approach can be developed for inhibiting
the pathological progression.
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